2. Search Result
Search Result
Results for "

total cholesterol

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

2

Natural
Products

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101812
    Terbufibrol

    		Others Metabolic Disease
    Terbufibrol has been shown highly active in reducing serum total cholesterol (TC) levels in the normal and hypercholesterolemic male rat.
    Terbufibrol
  • HY-152221
    PCSK9-IN-10

    		PCSK9 Cardiovascular Disease Metabolic Disease
    PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .
    PCSK9-IN-10
  • HY-163794
    DC371739

    		ANGPTL PCSK9 Metabolic Disease
    DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia .
    DC371739
  • HY-N13235
    Garlic Extract

    		Bacterial Antibiotic Cardiovascular Disease
    Garlic Extract is a garlic extract, and its components include: Allicin. Garlic Extract is beneficial to cardiovascular disease and has the potential to reduce the risk of cardiovascular disease. Garlic Extract can effectively reduce total cholesterol, low-density lipoprotein levels and improve high-density lipoprotein levels. .
    Garlic Extract
  • HY-N7729
    Sekikaic acid

    		Amylases Glycosidase Metabolic Disease
    Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .
    Sekikaic acid
  • HY-115914
    Lipid-lowering agent-1

    		LDLR Others
    Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .
    Lipid-lowering agent-1
  • HY-124560
    Lifibrol

    		Others Metabolic Disease
    Lifibrol is a potent and oral activity hypolipidemic agent. Lifibrol decreases the plasma total cholesterol. Lifibrol has the potential for the research of hypercholesterolemia .
    Lifibrol
  • HY-161942
    PCSK9-IN-31

    		PCSK9 Metabolic Disease
    PCSK9-IN-31 (Compound WX002) is an orally active PCSK9 inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats .
    PCSK9-IN-31
  • HY-W782122
    Photoclick cholesterol

    		Biochemical Assay Reagents Others
    Photoclick cholesterol is a sterol lipid cholesterol analog that contains a clickable terminal alkyne moiety and a photoactivatable diaziridine group. Photoclick cholesterol has the ability to photoaffinity label the mitochondrial outer membrane transport protein (TSPO) and is able to specifically bind cholesterol to TSPO. However, using excessive amounts of Photoclick cholesterol will reduce the photolabeling of total mitochondrial proteins and TSPO .
    Photoclick cholesterol
  • HY-B1209R
    Etofylline (Standard)

    		Phosphodiesterase (PDE) Cardiovascular Disease
    Etofylline (Standard) is the analytical standard of Etofylline. This product is intended for research and analytical applications. Etofylline (7-(β-Hydroxyethyl)theophylline) is a N-7-substituted derivative of Theophylline. Etofylline is a bronchodilator which can be used for the research of asthma. Etofylline is also an anticholesteremic and reduces total cholesterol level in the blood .
    Etofylline (Standard)
  • HY-168046
    ALG-055009

    		Thyroid Hormone Receptor Metabolic Disease
    ALG-055009 is a thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.063 μM. In rats on a high-fat diet, ALG-055009 can lower total cholesterol levels. ALG-055009 can be used in studies related to metabolic dysfunction-associated fatty liver disease .
    ALG-055009
  • HY-109089
    Epeleuton

    		Others Others
    Epeleuton is a second-generation synthetic n-3 fatty acid derivative that mainly targets the regulation of blood lipids, blood sugar and inflammatory responses. In clinical trials, Epeleuton significantly reduced triglycerides, very low-density lipoprotein cholesterol and total cholesterol without increasing low-density lipoprotein cholesterol levels. Epeleuton also significantly improved glycated hemoglobin (HbA1c) and fasting blood sugar levels. Epeleuton reduces markers of cardiovascular risk and endothelial dysfunction and has the potential to inhibit systemic inflammation and non-alcoholic fatty liver disease .
    Epeleuton
  • HY-158160
    LBA-3

    		Sodium Channel Metabolic Disease
    LBA-3 is a selective, orally active inhibitor for sodium-coupled citrate transporter SLC13A5, with an IC50 of 67 nM. LBA-3 decreases levels of triglyceride and total cholesterol in oleic and palmitic acid (OPA)-stimulated AML12 cells, PCN-stimulated primary mouse hepatocytes and in mouse models, without detectable toxicity. LBA-3 is blood-brain barrier permeable .
    LBA-3
  • HY-146398
    AMPK activator 6

    		AMPK Metabolic Disease
    AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
    AMPK activator 6
  • HY-W009732
    Sinapinic acid
    5 Publications Verification

    Sinapic acid

    		 HDAC Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of HDAC, with an IC50 of 2.27 mM , and also inhibits ACE-I activity . Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells . Sinapinic acid shows antioxidant and antidiabetic activities . Sinapinic acid reduces total cholesterol, triglyceride, and HOMA-IR index, and also normalizes some serum parameters of antioxidative abilities and oxidative damage in ovariectomized rats .
    Sinapinic acid
  • HY-W015600
    2-Acetamidophenol

    Orthocetamol

    		 Drug Isomer Inflammation/Immunology
    2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe 2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .
    2-Acetamidophenol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: